| Literature DB >> 26846279 |
Guanying Yu1, Lan Ye1, Wei Tan2, Xuguo Zhu1, Yaonan Li1, Duyin Jiang1.
Abstract
The extensive skin defects induced by severe burns are dangerous and can be fatal. Currently, the most common therapy is tangential excision to remove the necrotic or denatured areas of skin, followed by skin grafting. Xenogeneic dermal substitutes, such as porcine acellular dermal matrix (ADM), are typically used to cover the burn wounds, and may accelerate wound healing. It is assumed that burned skin that still maintains partial biological activity may be recycled to construct an autologous acellular dermal matrix, termed 'deep‑degree burned dermal matrix (DDBDM)'. In theory, DDBDM may avoid the histoincompatibility issues associated with foreign or xenogeneic dermal matrices, and reduce therapy costs by making full use of discarded skin. In the present study, the collagens within prepared DDBDM were thickened, disorganized and partially fractured, however, they still maintained their reticular structure and tensile strength (P<0.01). Through microarray analysis of the cytokines present in ADM and DDBDM, it was determined that the DDBDM did not produce excessive levels of harmful burn toxins. Following 4 weeks of subcutaneous implantation, ADM and DDBDM were incompletely degraded and maintained good integrity. No significant inflammatory reaction or rejection were observed, which indicated that ADM and DDBDM have good histocompatibility. Therefore, DDBDM may be a useful material for the treatment of deep‑degree burns.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26846279 PMCID: PMC4785012 DOI: 10.3892/mmr.2016.4866
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Figure 1ADM and DDBDM under general observation. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix.
Physical properties of acellular and deep-degree burned dermal matrix.
| Dermal matrix | Ultimate tensile strength, MPa | Maximum tension, N | Elongation at break, % | Strain at stress of 3 MPa, % |
|---|---|---|---|---|
| Acellular dermal matrix | 15.0±2.1 | 84±4 | 200±7 | 60.1±2.7 |
| Deep-degree burned dermal matrix | 10.2±1.8 | 57±3 | 182±5 | 41.6±1.4 |
| P-value | <0.05 | <0.01 | <0.05 | <0.01 |
Figure 2Hematoxylin and eosin and DAPI staining of normal skin, burned skin, ADM and DDBDM sections at various magnifications. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix.
Figure 3Biotinylated antibody cytokine microarray assay. (A) Images of the biotinylated antibody arrays. (B and C) Grid map of cytokines from the biotinylated antibody arrays. (D and E) Grid map of cytokine names from the biotinylated antibody microarrays.
Expression values of cytokines with significant differences between burned and normal skin samples.
| Cytokine | Normal skin | Burned skin | P-value | Fold change | ADM | DDBDM | P-value | Fold change |
|---|---|---|---|---|---|---|---|---|
| Activin βC | 393.5±61.5 | 1.0±0.0 | <0.01 | 393.500 | 76.5±0.5 | 34.0±3.0 | <0.01 | 2.250 |
| 6Ckine | 193.5±18.5 | 1.0±0.0 | <0.01 | 193.500 | 49.0±12.0 | 5.5±0.5 | <0.01 | 8.909 |
| Decorin | 49.0±11.0 | 1.0±0.0 | <0.01 | 49.000 | 913.5±76.5 | 180.0±6.0 | <0.01 | 5.075 |
| IL-10 | 1,460.0±94.0 | 336.0±8.0 | <0.01 | 4.345 | 221.0±7.0 | 98.0±1.0 | <0.01 | 2.255 |
| IL-17 | 1,057.5±46.5 | 268.5±60.5 | <0.01 | 3.939 | 180.0±8.0 | 107.5±3.5 | <0.01 | 1.674 |
| MMP-14 | 929.0±37.0 | 372.0±15.0 | <0.01 | 2.497 | 162.0±2.0 | 81.0±7.0 | <0.01 | 2.000 |
| HVEM | 1,193.5±118.5 | 499.0±212.0 | <0.01 | 2.392 | 219.5±1.5 | 68.5±1.5 | <0.01 | 3.204 |
| TNF-α | 1,327.0±32.0 | 637.5±18.5 | <0.01 | 2.082 | 184.0±17.0 | 107.0±4.0 | <0.01 | 1.720 |
| IL-3 | 2,519.0±33.0 | 1,356.5±56.5 | <0.01 | 1.857 | 303.0±15.0 | 145.5±3.5 | <0.01 | 2.082 |
| TGF-β1 | 1,205.5±111.5 | 688.5±39.5 | <0.01 | 1.751 | 212.0±22.0 | 115.5±4.5 | <0.01 | 1.835 |
| RELM β | 139.0±3.0 | 562.0±28.0 | <0.01 | 0.247 | 41.5±0.5 | 75.0±1.0 | <0.01 | 0.553 |
| IL-9 | 148.5±60.5 | 921.5±267.5 | <0.01 | 0.161 | 65.5±9.5 | 258.0±32.0 | <0.01 | 0.254 |
| IL-23 R | 12.8±13.2 | 157.5±46.5 | <0.01 | 0.081 | 2.5±2.2 | 14.5±4.5 | <0.05 | 0.172 |
| Thrombospondin | 20.5±26.0 | 907.0±46.0 | <0.01 | 0.023 | 25.5±14.5 | 65.5±9.5 | <0.05 | 0.389 |
Values are presented as mean ± standard deviation. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix; 6Ckine, Chemokine (C-C motif) ligand 21; IL, interleukin; MMP, matrix matelloproteinase; HVEM, herpesvirus entry mediator; TNF-α, tumor necrosis factor-α; TGF-β1, transforming growth factor-β1; RELM β, resistin-like molecule β; R, receptor.
Expression values of the cytokines with significant differences following cell extraction.
| Cytokine | Normal skin | ADM | P-value | Fold change | Burned skin | DDBDM | P-value | Fold change |
|---|---|---|---|---|---|---|---|---|
| RANTES | 115.0±7.0 | 9.0±7.0 | <0.01 | 12.778 | 208.5±102.5 | 19.0±10.0 | <0.05 | 10.974 |
| IL-6 | 2,195.0±32.0 | 226.0±20.0 | <0.01 | 9.712 | 3,129.0±4.0 | 131.5±9.5 | <0.01 | 23.795 |
| IL-3 | 2,519.0±33.0 | 303.0±15.0 | <0.01 | 8.314 | 1,356.5±56.5 | 145.5±3.5 | <0.01 | 9.323 |
| TNF-α | 1,327.0±32.0 | 184.0±17.0 | <0.01 | 7.212 | 637.5±18.5 | 107.0±4.0 | <0.01 | 5.958 |
| IL-10 | 1,460.0±94.0 | 221.0±7.0 | <0.01 | 6.606 | 336.0±8.0 | 98.0±1.0 | <0.01 | 3.429 |
| GDF-1 | 316.5±6.5 | 50.5±14.5 | <0.01 | 6.267 | 155.5±23.5 | 53.0±1.0 | <0.01 | 2.934 |
| IL-12 p70 | 2,000.5±120.5 | 322.0±11.0 | <0.01 | 6.213 | 1,984.5±21.5 | 150.0±16.0 | <0.01 | 13.230 |
| IFN-β | 1,117.5±6.5 | 182.0±9.0 | <0.01 | 6.140 | 1,252.0±85.0 | 136.0±5.0 | <0.01 | 9.206 |
| MCP-1 | 1,125.0±20.0 | 187.5±12.5 | <0.01 | 6.000 | 829.5±89.5 | 89.5±0.5 | <0.01 | 9.268 |
| IFN-γ | 1,990.5±81.5 | 332.5±6.5 | <0.01 | 5.986 | 1,357.5±75.5 | 163.0±1.0 | <0.01 | 8.328 |
| CD11b | 2,094.0±231.0 | 355.5±4.5 | <0.01 | 5.890 | 1,527.0±80.0 | 152.0±6.0 | <0.01 | 10.046 |
| IL-17 | 1,057.5±46.5 | 180.0±8.0 | <0.01 | 5.875 | 268.5±60.5 | 107.5±3.5 | <0.05 | 2.498 |
| MMP-14 | 929.0±37.0 | 162.0±2.0 | <0.01 | 5.735 | 372.0±15.0 | 81.0±7.0 | <0.01 | 4.593 |
| TGF-β1 | 1,205.5±111.5 | 212.0±22.0 | <0.01 | 5.686 | 688.5±39.5 | 115.5±4.5 | <0.01 | 5.961 |
| IL-5 | 1,112.0±44.0 | 202.0±4.0 | <0.01 | 5.505 | 1,073.5±90.5 | 118.0±4.0 | <0.01 | 9.097 |
| IL-12 p40/p70 | 1,288.0±44.0 | 235.5±3.5 | <0.01 | 5.469 | 1,111.5±80.5 | 118.5±12.5 | <0.01 | 9.380 |
| HVEM | 1,193.5±118.5 | 219.5±1.5 | <0.01 | 5.437 | 499.0±212.0 | 68.5±1.5 | <0.05 | 7.285 |
| IL-5 R α | 339.0±65.0 | 81.5±0.5 | <0.01 | 4.160 | 370.0±37.0 | 50.0±3.0 | <0.01 | 7.400 |
| RELM β | 139.0±3.0 | 41.5±0.5 | <0.01 | 3.349 | 562.0±28.0 | 75.0±1.0 | <0.01 | 7.493 |
| IL-1 R9 | 48.5±49.6 | 465.0±5.0 | <0.01 | 0.104 | 1.0 ±0.0 | 29.0±3.0 | <0.01 | 0.034 |
| MMP-9 | 1.0±0.0 | 15.0±3.0 | <0.01 | 0.067 | 1.0±0.0 | 219.5±21.5 | <0.01 | 0.005 |
| Decorin | 49.0±11.0 | 913.5±76.5 | <0.01 | 0.054 | 1.0±0.0 | 180.0±6.0 | <0.01 | 0.006 |
| IL-2 R γ | 1.0±0.0 | 164.5±3.5 | <0.01 | 0.006 | 1.0±0.0 | 109.0±3.0 | <0.01 | 0.009 |
Values are presented as mean ± standard deviation. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix; RANTES, regulated on activation normal T cell and secreted; IL, interleukin; TNF-α, tumor necrosis factor-α; GDF-1, embryonic growth/differentiation factor 1; IFN-β, interferon; MCP-1, monocyte chemotactic protein-1; MMP, matrix metalloproteinase; TGF-β1, transforming growth factor-β1; HVEM, herpesvirus entry mediator; R, receptor; RELM β, resistin-like molecule β.
Expression values of the cytokines with significant differences between ADM and DDBDM.
| Cytokine | ADM | DDBDM | Fold change | P-value |
|---|---|---|---|---|
| IL-1 R9 | 465.0±5.0 | 29.0±3.0 | 16.034 | <0.01 |
| Decorin | 913.5±76.5 | 180.0±6.0 | 5.075 | <0.01 |
| HVEM | 219.5±1.5 | 68.5±1.5 | 3.204 | <0.01 |
| CD11b | 355.5±4.5 | 152.0±6.0 | 2.339 | <0.01 |
| IL-10 | 221.0±7.0 | 98.0±1.0 | 2.255 | <0.01 |
| IL-12 p70 | 322.0±11.0 | 150.0±16.0 | 2.147 | <0.01 |
| MCP-1 | 187.5±12.5 | 89.5±0.5 | 2.095 | <0.01 |
| IL-3 | 303.0±15.0 | 145.5±3.5 | 2.082 | <0.01 |
| IFN-γ | 332.5±6.5 | 163.0±1.0 | 2.040 | <0.01 |
| MMP-14 | 162.0±2.0 | 81.0±7.0 | 2.000 | <0.01 |
| IL-12 p40/p70 | 235.5±3.5 | 118.5±12.5 | 1.987 | <0.01 |
| TGF-β1 | 212.0±22.0 | 115.5±4.5 | 1.835 | <0.01 |
| TNF-α | 184.0±17.0 | 107.0±4.0 | 1.720 | <0.01 |
| IL-6 | 226.0±20.0 | 131.5±9.5 | 1.719 | <0.01 |
| IL-5 | 202.0±4.0 | 118.0±4.0 | 1.712 | <0.01 |
| IL-17 | 180.0±8.0 | 107.5±3.5 | 1.674 | <0.01 |
| IL-2 R γ | 164.5±3.5 | 109.0±3.0 | 1.509 | <0.01 |
| IL-9 | 65.5±9.5 | 258.0±32.0 | 0.254 | <0.01 |
| MMP-9 | 15.0±3.0 | 219.5±21.5 | 0.068 | <0.01 |
Values are presented as mean ± standard deviation. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix; IL, inter-leukin; R, receptor; HVEM, herpesvirus entry mediator; MCP-1, monocyte chemotactic protein-1; INF-γ, interferon-γ; MMP, matrix metalloproteinase; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α.
Figure 4General observations following subcutaneous implantation of the ADM and DDBDM. (A) The healed wound 1 and 4 weeks after subcutaneous implantation. (B) Images of the subcutaneously implanted ADM (left) and DDBDM (right) after 1, 2, 3 and 4 weeks. (C) Comparison of the ADM and DDBDM after they were separated from the skin. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix.
Figure 5Area of ADM and DDBDM following subcutaneous implantation. Values are presented as mean ± standard deviation. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix.
Figure 6Histopathological observations of the ADM and DDBDM 1, 2, 3 and 4 weeks after subcutaneous implantation. Hematoxylin and eosin staining. ADM, acellular dermal matrix; DDBDM, deep-degree burned dermal matrix.